U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2003
181
Substance Class Protein
Created
by admin
on Mon Mar 31 18:35:20 GMT 2025
Edited
by admin
on Mon Mar 31 18:35:20 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
2P471X1Z11
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
OMALIZUMAB
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
OMALIZUMAB (GENETICAL RECOMBINATION)
JAN  
Preferred Name English
Omalizumab [WHO-DD]
Common Name English
OMALIZUMAB [MART.]
Common Name English
OMALIZUMAB [PURPLE BOOK CDER]
Common Name English
RG-3648
Code English
IGE25
Code English
OMALIZUMAB [JAN]
Common Name English
OMALIZUMAB [EMA EPAR]
Common Name English
omalizumab [INN]
Common Name English
OMALIZUMAB [VANDF]
Common Name English
RHUMAB-E25
Code English
XOLAIR
Brand Name English
OMALIZUMAB [MI]
Common Name English
OMALIZUMAB [USAN]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548822
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
NDF-RT N0000175794
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
NDF-RT N0000175793
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
NDF-RT N0000175793
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
EMA ASSESSMENT REPORTS XOLAIR(AUTHORIZED: ASTHMA, URTICARIA)
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
WHO-ATC R03DX05
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
WHO-VATC QR03DX05
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
NDF-RT N0000175792
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
NCI_THESAURUS C20401
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
Code System Code Type Description
JAPANESE REVIEW
XOLAIR
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY APPROVE JANUARY 2009
NCI_THESAURUS
C29299
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
DAILYMED
2P471X1Z11
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
INN
8039
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
WIKIPEDIA
OMALIZUMAB
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201589
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
FDA UNII
2P471X1Z11
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
MESH
C426106
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
CAS
242138-07-4
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
DRUG CENTRAL
4972
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
HSDB
8176
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
EVMPD
SUB12543MIG
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
USAN
KK-77
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
RXCUI
302379
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY RxNorm
SMS_ID
100000089291
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
IUPHAR
6890
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
MERCK INDEX
m8206
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY Merck Index
LACTMED
Omalizumab
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
DRUG BANK
DB00043
Created by admin on Mon Mar 31 18:35:20 GMT 2025 , Edited by admin on Mon Mar 31 18:35:20 GMT 2025
PRIMARY
From To
1_22 1_96
1_148 1_204
1_224 3_218
1_230 2_230
1_233 2_233
1_265 1_325
1_371 1_429
2_22 2_96
2_148 2_204
2_224 4_218
2_265 2_325
2_371 2_429
3_23 3_92
3_138 3_198
4_23 4_92
4_138 4_198
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_301
N 2_301
Related Record Type Details
OMALIZUMAB BIOSIMILAR (CT-P39)
SUB_CONCEPT->SUBSTANCE
IMMUNOGLOBULIN E HEAVY CHAIN CONSTANT REGION
TARGET -> INHIBITOR
Omalizumab inhibits the binding of IgE to Fc?RI on mast cells and basophils by binding to an antigenic epitope on IgE that overlaps with the site to which Fc?RI binds.
BINDING
SYN-008
SUB_CONCEPT->SUBSTANCE
GBR-310
SUB_CONCEPT->SUBSTANCE
GBR-310
BIOSIMILAR -> PARENT
SYN-008
BIOSIMILAR -> PARENT
OMALIZUMAB BIOSIMILAR (CT-P39)
BIOSIMILAR -> PARENT
Related Record Type Details
OMALIZUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966